title: TRAIL shows potential cardioprotective activity.
abstract: Recent clinical trials carried out in patients with advanced cancer have shown that recombinant TRAIL administration is usually safe and well tolerated when used either alone or in association with chemotherapeutic drugs. Notably, anticancer chemotherapy can be associated to cardiomiopathy. We have here demonstrated that TRAIL (administrated as either recombinant soluble TRAIL or as AAV-TRAIL expression viral vector) reduced the development of cardiomyopathy in the ApoE(-/-) diabetic mouse model. These data suggest, for the first time, that therapeutically administration of TRAIL might have a cardioprotective effect.
authors.affiliation: Institute for Maternal and Child Health, IRCCS Burlo Garofolo, Trieste, Italy.
authors.forename: Barbara
authors.initials: B
authors.lastname: Toffoli
authors.forename: Stella
authors.initials: S
authors.lastname: Bernardi
authors.forename: Riccardo
authors.initials: R
authors.lastname: Candido
authors.forename: Serena
authors.initials: S
authors.lastname: Zacchigna
authors.forename: Bruno
authors.initials: B
authors.lastname: Fabris
authors.forename: Paola
authors.initials: P
authors.lastname: Secchiero
mesh_terms: D000818:Animals; D001057:Apolipoproteins E / Q000172:deficiency / Q000235:genetics; D017209:Apoptosis / Q000187:drug effects; D002316:Cardiotonic Agents / Q000627:therapeutic use*; D003921:Diabetes Mellitus, Experimental / Q000188:drug therapy*; D003922:Diabetes Mellitus, Type 1 / Q000188:drug therapy* / Q000473:pathology; D058065:Diabetic Cardiomyopathies / Q000188:drug therapy* / Q000473:pathology; D005355:Fibrosis; D008297:Male; D051379:Mice; D018345:Mice, Knockout; D011994:Recombinant Proteins / Q000627:therapeutic use; D053221:TNF-Related Apoptosis-Inducing Ligand / Q000627:therapeutic use*
chemical_list: D001057:Apolipoproteins E; D002316:Cardiotonic Agents; D011994:Recombinant Proteins; D053221:TNF-Related Apoptosis-Inducing Ligand